Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Short-term Investments (2016 - 2025)

Arrowhead Pharmaceuticals' Short-term Investments history spans 15 years, with the latest figure at $715.0 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 43.27% year-over-year to $715.0 million; the TTM value through Dec 2025 reached $715.0 million, up 43.27%, while the annual FY2025 figure was $692.8 million, 19.81% up from the prior year.
  • Short-term Investments reached $715.0 million in Q4 2025 per ARWR's latest filing, up from $692.8 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $911.7 million in Q1 2025 to a low of $56.6 million in Q3 2021.
  • Average Short-term Investments over 5 years is $374.4 million, with a median of $322.8 million recorded in 2022.
  • Peak YoY movement for Short-term Investments: soared 373.96% in 2022, then tumbled 45.89% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $126.0 million in 2021, then soared by 137.76% to $299.6 million in 2022, then crashed by 45.89% to $162.1 million in 2023, then soared by 207.86% to $499.0 million in 2024, then skyrocketed by 43.27% to $715.0 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Short-term Investments are $715.0 million (Q4 2025), $692.8 million (Q3 2025), and $770.6 million (Q2 2025).